Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?

Advances in Therapy

Volumn 28, Issue 11, 2011, Pages 973-985

  Aftimos, Philippe ^a   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

anthracyclines; capecitabine; clinical trials; eribulin mesylate; metastatic breast cancer; microtubules; taxanes

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERIBULIN; GAMMA UROGASTRONE; GRANULOCYTE COLONY STIMULATING FACTOR; HALICHONDRIN B; IXABEPILONE; NANOPARTICLE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; UNITED STATES; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; ETHERS, CYCLIC; FEMALE; FURANS; HUMANS; KETONES; MICROTUBULES; NEOPLASM METASTASIS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 82355191648     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0070-9     Document Type: Review

References (56)

1. R. Siegel E. Ward O. Brawley A. Jemal 2011 Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin. 61 212 236 21685461 10.3322/caac.20121
2. J. Ferlay P. Autier M. Boniol, et al. 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol. 18 581 592 17287242 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D (Pubitemid 46359643)
3. G. Mariani 2005 New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy Ann Oncol. 16 Suppl.2 191 194
4. S.K. Chia C.H. Speers Y. D'yachkova, et al. 2007 The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer Cancer. 110 973 979 17647245 10.1002/cncr.22867 (Pubitemid 47312861)
5. Breast cancer facts and figures 2009-2010. Available at: http://www.cancer.org/Research/CancerFactsFigures/BreastCancerFactsFigures/ breastcancer-facts-figures-2009-2010. Last accessed July 1, 2011.
6. C. Bernard-Marty F. Cardoso M.J. Piccart 2004 Facts and controversies in systemic treatment of metastatic breast cancer Oncologist. 9 617 632 15561806 10.1634/theoncologist.9-6-617 (Pubitemid 39546403)
7. S.E. Jones 2008 Metastatic breast cancer: the treatment challenge Clin Breast Cancer. 8 224 233 18650152 10.3816/CBC.2008.n.025 1:CAS:528: DC%2BD1cXovFCiu7s%3D (Pubitemid 351962143)
8. F. Cardoso P.L. Bedard E.P. Winer, et al. 2009 ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy J Natl Cancer Inst. 101 1174 1781 19657108 10.1093/jnci/djp235 1:CAS:528:DC%2BD1MXhtFWhu73J
9. K.S. Albain S.M. Nag G. Calderillo-Ruiz, et al. 2008 Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol. 26 3950 3957 18711184 10.1200/JCO.2007.11.9362
10. J. O'shaughnessy D. Miles S. Vukelja, et al. 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol. 20 2812 2823 12065558 10.1200/JCO.2002.09.002 (Pubitemid 34651510)
11. Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;(2):CD003372.
12. National Comprehensive Cancer Network. 2011 NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/breast.pdf. Last accessed July 1, 2011.
13. W.J. Gradishar S. Tjulandin N. Davidson, et al. 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol. 23 7794 7803 16172456 10.1200/JCO.2005.04.937 1:CAS:528:DC%2BD2MXht1Cqs7nK (Pubitemid 46657376)
14. F.Y. Lee R. Borzilleri C.R. Fairchild, et al. 2008 Preclinical discovery of ixabepilone, a highly active antineoplastic agent Cancer Chemother Pharmacol. 63 157 166 18347795 10.1007/s00280-008-0724-8 1:CAS:528:DC%2BD1cXhtF2kur%2FM
15. F.Y. Lee R. Smykla K. Johnston, et al. 2009 Preclinical efficacy spectrum and pharmacokinetics of ixabepilone Cancer Chemother Pharmacol. 63 201 212 18350296 10.1007/s00280-008-0727-5 1:CAS:528:DC%2BD1cXhsVelurjJ
16. E.S. Thomas H.L. Gomez R.K. Li, et al. 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol. 25 5210 5217 17968020 10.1200/JCO.2007.12.6557 1:CAS:528:DC%2BD2sXhsVKnsbzO (Pubitemid 350232252)
17. Hortobagyi G, Perez E, Vrdoljak E, et al. Analysis of overall survival among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone plus capecitabine or capecitabine alone: results from two randomized phase III trials. In Proceedings of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, 5-7 Sep 2008, (Abstr 186). Washington, DC.
18. D. Uemura K. Takahashi T. Yamamoto, et al. 1985 An antitumor polyether macrolide from a marine sponge J Am Chem Soc. 107 4796 4798 10.1021/ja00302a042 1:CAS:528:DyaL2MXksFWntL8%3D (Pubitemid 16244006)
19. Y. Hirata D. Uemura 1986 Halichondrins: antitumor polyether macrolides from a marine sponge Pure Appl Chem. 58 701 710 10.1351/pac198658050701 1:CAS:528:DyaL28XlvVOqsLs%3D (Pubitemid 16557441)
20. M.J. Towle K.A. Salvato J. Budrow, et al. 2001 In vitro and in vivo anticancer activities of synthetic macrocyclicketone analogs of halichondrin B Cancer Res. 61 1013 1021 11221827 1:CAS:528:DC%2BD3MXhsFSru7k%3D (Pubitemid 32174419)
21. G. Kuznetsov M.J. Towle H. Cheng, et al. 2004 Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 Cancer Res. 64 5760 5766 15313917 10.1158/0008-5472.CAN-04-1169 1:CAS:528:DC%2BD2cXmslaksrw%3D (Pubitemid 39095575)
22. R.F. Luduena M.C. Roach V. Prasad G.R. Pettit 1993 Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin Biochem Pharmacol. 45 421 427 8435093 10.1016/0006-2952(93)90079-C 1:CAS:528: DyaK3sXit1ymsbc%3D (Pubitemid 23042642)
23. M.A. Jordan K. Kamath T. Manna, et al. 2005 The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol Cancer Ther. 4 1086 1095 16020666 10.1158/1535-7163.MCT- 04-0345 1:CAS:528:DC%2BD2MXmtFSltrY%3D (Pubitemid 41079102)
24. G. Kuznetsov K. TenDyke M.J. Yu B.A. Littlefield 2007 Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxelresistant human cancer cells in vitro AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics - Oct 22-26, 2007; San Francisco, CA. Proc Am Assoc Cancer Res 48 275
25. S. Goel A.C. Mita M. Mita, et al. 2009 A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies Clin Cancer Res. 15 4207 4212 19509177 10.1158/1078-0432.CCR-08-2429 1:CAS:528:DC%2BD1MXntlOisbY%3D
26. A.R. Tan E.H. Rubin D.C. Walton, et al. 2009 Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors Clin Cancer Res. 15 4213 4219 19509146 10.1158/1078-0432.CCR-09-0360 1:CAS:528:DC%2BD1MXntlOisbc%3D
27. L.T. Vahdat B. Pruitt C.J. Fabian, et al. 2009 Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol. 27 2954 2961 19349550 10.1200/JCO.2008.17.7618 1:CAS:528:DC%2BD1MXoslyis74%3D
28. J. Cortes L. Vahdat J.L. Blum, et al. 2010 Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine J Clin Oncol. 28 3922 3928 20679609 10.1200/JCO.2009.25.8467 1:CAS:528:DC%2BC3cXht1eqsbzM
29. J. Cortes J. O'shaughnessy D. Loesch, et al. 2011 EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulinmonotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 377 914 923 21376385 10.1016/S0140-6736(11)60070-6 1:CAS:528:DC%2BC3MXjtFWgs7c%3D
30. Eisai Inc. A study of single-agent eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor two (HER2) negative breast cancer. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available from: http://clinicaltrials.gov/show/NCT01268150 NLM identifier: NCT01268150.
31. Eisai Inc. A study comparing eribulin mesylate and ixabepilone in causing or exacerbating neuropathy in patients with advanced breast cancer. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/ NCT00879086 NLM identifier: NCT00879086.
32. Northwestern University. Carboplatin and eribulin mesylate in triple negative breast cancer patients. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/NCT01372579 NLM identifier: NCT01372579.
33. Eisai Inc. Eribulin with trastuzumab as firstline therapy for locally recurrent or metastatic HER2 positive breast cancer. In: ClinicalTrials. gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/NCT01269346 NLM identifier: NCT01269346.
34. ACORN Research LLC. Study of neoadjuvantcarboplatin, eribulin and trastuzumab for operable HER2 positive breast cancer. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/NCT01388647 NLM identifier: NCT01388647.
35. Eisai Inc. Dose dense doxorubucin and cyclophosphamide followed by eribulin mesylate for the adjuvant treatment of early stage breast cancer. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/ NCT01328249 NLM identifier: NCT01328249.
36. California Cancer Consortium. E7389 and Cisplatin in treating patients with advanced solid tumors. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/NCT00415324 NLM identifier: NCT00415324.
37. Eisai Limited. A phase 1b/2, multicenter, randomized, open-label, dose-escalation and confirmation study of eribulin in combination with capecitabine. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/ show/NCT01323530 NLM identifier: NCT01323530.
38. Eisai Inc. An open-label, multi-center, expanded access program with eribulin for the treatment of advanced breast cancer refractory. In: ClinicalTrials. gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/ NCT01240421 NLM identifier: NCT01240421.
39. Eisai Inc. A dose-finding study of E7389 in combination with carboplatin in patients with solid tumors. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/NCT00268905 NLM identifier: NCT00268905.
40. Eisai Inc. Compassionate use of eribulin for the treatment of advanced breast cancer refractory to all other marketed therapies. In: ClinicalTrials. gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/NCT01142661 NLM identifier: NCT01142661.
41. Eisai Inc. E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/ NCT00337103 NLM identifier: NCT00337103.
42. Goel R, Chen E, Welch S, et al. Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol. 2009;27(Suppl.). Abstract e13509.
43. U. Swami D.P. Petrylak H. Raftopoulos, et al. 2010 Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors J Clin Oncol Meeting Abstracts. 28 Suppl. 15
44. Sanofi-Aventis. 2000 Combination chemotherapy with or without trastuzumab in treating women with breast cancer ClinicalTrials.gov National Library of Medicine (US) Bethesda (MD)
45. Sanofi-Aventis. Combination chemotherapy with or without trastuzumab in treating women with breast cancer. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 4]. Available at: http://clinicaltrials.gov/show/NCT00021255 NLM identifier: NCT00021255.
46. Twelves C, Vahdat LT, Cortes J, et al. The relationship between age and survival outcomes for eribulin in metastatic breast cancer. J Clin Oncol. 2011;29(Suppl.). Abstract 1060.
47. T.W. Synold R.J. Morgan E.M. Newman, et al. 2005 A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial J Clin Oncol 23 16S 3036
48. Mukohara T, Nagai S, Mukai H, Namiki M, Minami H. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest New Drugs. 2011 Sep 2. [Epub ahead of print]
49. A. Gupta D.R. Mould L. Reyderman, et al. 2010 Population pharmacokinetic-pharmacodynamic (PK/PD) analysis of safety and efficacy of eribulin in metastatic or loclly advanced breast cancer patients Ann Oncol. 21 Suppl.8 viii96 viii121
50. Devriese L, Wanders J, Jenner A, et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET). 22nd EORTC-AACR-NCI meeting, Berlin, Germany, November 16-19, 2010. Abstract 574.
51. P. Witteveen S. Marchetti M. Mergui-Roelvink, et al. 2010 Eribulin mesylate pharmacokinetics in patients with hepatic impairment J Clin Oncol. 28 Suppl. 15s
52. Devriese LA, Witteveen P, Voest EE, et al. Eribulin dosing in patients with advanced solid tumors and hepatic impairment. J Clin Oncol. 2011;29(Suppl.):Abstr 2544.
53. H. Iwata K. Aogi N. Masuda, et al. 2010 Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer J Clin Oncol. 28 Suppl. 15s
54. P. Seve J. Mackey S. Isaac, et al. 2005 Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel Mol Cancer Ther. 4 2001 2007 16373715 10.1158/1535-7163.MCT-05-0244 1:CAS:528:DC%2BD2MXhtlCnsrjI (Pubitemid 43056983)
55. R. Rouzier R. Rajan P. Wagner, et al. 2005 Microtubuleassociated protein tau: a marker of paclitaxel sensitivity in breast cancer Proc Natl Acad Sci USA. 102 8315 8320 15914550 10.1073/pnas.0408974102 1:CAS:528:DC%2BD2MXlsV2mtLc%3D (Pubitemid 40800086)
56. A. Jimeno G. Hallur A. Chan, et al. 2007 Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer Mol Cancer Ther. 6 1509 1516 17483439 10.1158/1535-7163.MCT-06-0592 1:CAS:528: DC%2BD2sXotFaltL4%3D (Pubitemid 46954017)